JMP ups Oscient price target to $18, rates at strong buy

JMP Securities analyst Adam Cutler rated Oscient Pharmaceuticals Corp. at a strong buy and raised the price target to $18, or 8 times the previous price target of $2.25. The analyst adjusted his model and price target due to the company's reverse split. Newly acquired Antara could be a major catalyst for Oscient shares. Shares of the Waltham, Mass., biopharmaceutical company were up 49 cents, or 6.38%, at $8.00. (Nasdaq: OSCID)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.